Skip to content

Main Menu

Company
Products and Pipeline
Investors
Careers
News
Contact Us

Main Menu

Company
Products and Pipelines
Investors
Careers
News
Contact Us

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

Company

PRODUCTS AND PIPELINE
Leadership Team
Board
Partnerships
Contact Us
Sustainability
Medical Educational Grants
Investigator Sponsored Trials
CALIFORNIA COMPLIANCE DECLARATION

Investors

Investor Relations
Financials And Filings
Corporate Governance
Analyst coverage
FAQ
Press Releases

Careers

Opportunities
Culture
Benefits
Privacy Notice

Media

News

Company

PRODUCTS AND PIPELINE
LEADERSHIP TEAM
BOARD
PARTNERSHIPS
CONTACT US
SUSTAINABILITY
MEDICAL EDUCATIONAL GRANTS
INVESTIGATOR SPONSORED TRIALS
CALIFORNIA COMPLIANCE DECLARATION

Investors

INVESTOR RELATIONS
FINANCIALS & FILINGS
CORPORATE GOVERNANCE
ANALYST COVERAGE
STOCK INFORMATION
FAQ
PRESS RELEASES

Careers

OPPORTUNITIES
CULTURE
BENEFITS

Media

NEWS

Facebook-f Instagram Twitter Linkedin-in

For customer service, product information, new accounts or adverse events call: 877-3REV-NOW

1222 Demonbreun St
20th Floor
Nashville, TN 37203

©2023 REVANCE AESTHETICS. REVANCE THERAPEUTICS AND THE REVANCE LOGO ARE REGISTERED TRADEMARKS OF REVANCE. DAXI - 003290.2

Social Media Community Guidelines
Privacy Policy
Terms of Use

Social Media Community Guidelines
Privacy Policy
Terms of Use